A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

Recurrent or Metastatic Cervical Cancer Clinical Trial

Official title: Efficacy and Safety of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer: a Multicenter, Prospective, Real-world Study

Status Not yet recruiting

Clinical Trial Summary

This real-world study included all patients with recurrent or metastatic cervical cancer who used Cadonilimab in clinical practice, regardless of treatment lines and combination with different treatments. Through follow-up observations, the aim of this study is to analyze the efficacy of Cadonilimab for recurrent or metastatic cervical cancer in the real world, and to explore the differences in the efficacy of Cadonilimab in different stages of treatment, as well as the efficacy of different treatment combinations, so as to provide clinical evidence for the use of Cadonilimab for recurrent or metastatic cervical cancer.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Recurrence
• Recurrent or Metastatic Cervical Cancer
• Uterine Cervical Neoplasms

• NCT number: NCT06155422
• Study type: Observational
• Source: Tongji Hospital
• Contact: Ding Ma
• Phone: 86-027-8362681
• Email: dma@tjh.tjmu.edu.cn
• Status: Not yet recruiting
• Start date: November 30, 2023
• Completion date: November 30, 2027